Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Karsten Roth, Dirk Lehnick, Hendrik Wessels, et al.
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Hendrik Wessels, Dirk Lehnick, Josef Höfler, et al.
CNS Drugs
|
February 28, 2024
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants
Andreas W Wolff, Jörg Peine, Josef Höfler, et al.
Global Change Biology
|
December 11, 2013
Chilling outweighs photoperiod in preventing precocious spring development
Julia Laube, Tim H Sparks, Nicole Estrella, et al.
Journal of Experimental Botany
|
May 1, 2013
Nutrient status: a missing factor in phenological and pollen research?
Susanne Jochner, Josef Höfler, Isabelle Beck, et al.
JAMA Neurology
|
January 23, 2023
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, Heinz Wiendl, Karsten Roth, et al.
Frontiers in Immunology
|
January 3, 2025
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile
Paul Chamberlain, Bernhard Hemmer, Josef Höfler, et al.
Expert Opinion on Biological Therapy
|
December 4, 2023
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial
Hendrik Wessels, Oliver von Richter, Maria Velinova, et al.
Breast Care (Basel, Switzerland)
|
January 14, 2014
Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers
Joachim Rom, Claudia Schumacher, Oleg Gluz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
September 29, 2024
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Krzysztof Selmaj, Karsten Roth, Josef Höfler, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Karsten Roth, Dirk Lehnick, Hendrik Wessels, et al.
Pharmacology Research & Perspectives
|
August 17, 2019
Pharmacodynamics, safety, and immunogenicity of Pelmeg<sup>®</sup>, a pegfilgrastim biosimilar in healthy subjects
Hendrik Wessels, Dirk Lehnick, Josef Höfler, et al.
CNS Drugs
|
February 28, 2024
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants
Andreas W Wolff, Jörg Peine, Josef Höfler, et al.
Global Change Biology
|
December 11, 2013
Chilling outweighs photoperiod in preventing precocious spring development
Julia Laube, Tim H Sparks, Nicole Estrella, et al.
Journal of Experimental Botany
|
May 1, 2013
Nutrient status: a missing factor in phenological and pollen research?
Susanne Jochner, Josef Höfler, Isabelle Beck, et al.
JAMA Neurology
|
January 23, 2023
Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
Bernhard Hemmer, Heinz Wiendl, Karsten Roth, et al.
Frontiers in Immunology
|
January 3, 2025
Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile
Paul Chamberlain, Bernhard Hemmer, Josef Höfler, et al.
Expert Opinion on Biological Therapy
|
December 4, 2023
Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial
Hendrik Wessels, Oliver von Richter, Maria Velinova, et al.
Breast Care (Basel, Switzerland)
|
January 14, 2014
Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers
Joachim Rom, Claudia Schumacher, Oleg Gluz, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
September 29, 2024
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
Krzysztof Selmaj, Karsten Roth, Josef Höfler, et al.
Page
of 2